Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

M 1231

Next Previous
Drug Profile

M 1231

Alternative Names: Bispecific anti-MUC1xEGFR antibody-drug conjugate; M-1231; MUC1/EGFR bi-specific ADC

Latest Information Update: 21 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sutro Biopharma
  • Developer EMD Serono; Merck KGaA
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 26 Jun 2023 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Refractory metastatic disease) in Canada (Parenteral) (Sutro Biopharma pipeline, June 2023)
  • 26 Jun 2023 Discontinued - Phase-I for Oesophageal cancer (Late-stage disease, Refractory metastatic disease) in Canada (Parenteral) (Sutro Biopharma pipeline, June 2023)
  • 26 Jun 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Refractory metastatic disease) in Canada (Parenteral) (Sutro Biopharma pipeline, June 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top